Collegium Pharmaceutical (COLL) EBITDA Margin (2016 - 2026)

Collegium Pharmaceutical has reported EBITDA Margin for 11 years, with the latest figure at 2.76% in Q2 2026.

• On a quarterly basis, EBITDA Margin fell 1652.0% year-over-year to 2.76% in Q2 2026; TTM through Jun 2026 was 19.76%, a 110.0% increase from a year earlier, with the FY2025 full-year figure at 23.55%, down 397.0% from the prior year.
• EBITDA Margin was 2.76% for Q2 2026 at Collegium Pharmaceutical, down from 16.2% in the prior quarter.
• The five-year high for EBITDA Margin was 41.2% in Q4 2023, with the low at 11.96% in Q1 2022.
• Average EBITDA Margin over 5 years is 19.94%, with a median of 20.11% recorded in 2024.
• The largest YoY upside for EBITDA Margin was 13306 bps in 2022 against a maximum downside of 3612 bps in 2022.
• Over 5 years, EBITDA Margin stood at 8.36% in 2022, then surged by 393 bps to 41.2% in 2023, then tumbled by 49 bps to 20.95% in 2024, then jumped by 41 bps to 29.57% in 2025, then sank by 91 bps to 2.76% in 2026.
• The last three EBITDA Margin figures came in at 2.76% (Q2 2026), 16.2% (Q1 2026), and 29.57% (Q4 2025), per Business Quant data.